graph Evidence gap map comparisons
atezolizumab based treatmentnivolumab based treatmentanti-PD-(L)1pembrolizumab based treatmentpembrolizumab alonepembrolizumab based treatment
atezolizumab plus cometinib atezolizumab plus SoC nivolumab alone nivolumab followed by ipilimumab pembrolizumab alone pembrolizumab (10mg/kg) pembrolizumab (10mg/kg) 2 weeks pembrolizumab (2mg/kg) pembrolizumab plus SoC
mML - (neo)adjuvant (NA)
mML - NA - all population 9      
mML - NA - PDL1 positive 1   
mML - 1st line (L1)
mML - L1 - all population 7     
mML - L1 - BRAF mutant 2   
mML - L1 - BRAF wild 3     
mML - 2nd line (L2)
mML - L2 - all population 11          
mML - L2 - BRAF mutant 1   
Comparator:  vs ipilimumab alone;   vs ipilimumab followed by nivolumab;   vs placebo plus SoC;   vs pembrolizumab alone;   vs dacarbazine;   vs Standard of Care (SoC);   vs Ipilimumab (10 mg/kg);   vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;